ESMM Biosensor for Personalized Phagocytosis Quantification in Infections



A) Biosensor cross-sectional schematic demonstrating phagocyte with microparticles through sensing region B) Corresponding bipolar pulse generated with each passage of the cell C) Top view of biosensor where magnetic is placed on side to generate field and to modulate the cell speed

Invention Summary:

Point-of-care biomedical technologies are crucial for early infection diagnosis, risk stratification, and effective treatment response evaluation. However, developing these sensors involves overcoming technological challenges and integrating multiple fields, while current clinical instruments are costly and time-consuming.

Rutgers researchers have developed an invention that introduces a personalized biosensor that not only measures phagocytic ability but also enhances it through on-chip immune-engineering. The automated sensor provides phagocytic ability results from a drop of whole blood in just ~15 minutes, using electromagnetic biosensing, real-time measurement, and machine learning for accuracy improvement, with testing on patient samples from Robert Wood Johnson Medical Hospital.  .

Market Applications:

  • Biochip to quantify phagocytic ability
  • Early diagnosis and prognosis of infected patients
  • Stratifying high-risk patients
  • Determining effective therapeutic response


  • It can quantify the phagocytic ability of blood cells in ~15 minutes
  • Cost-effective

Publications:  ESMM Biosensor  



Intellectual Property & Development Status: Patent pending. Available for licensing and/or research collaboration. For any business development and other collaborative partnerships contact:

Patent Information:
Lisa Lyu
Assistant Director
Rutgers, The State University of New Jersey